Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	hormone receptor-positive breast cancer	Recruiting	Phase 2	2026-07-16		NCT05467891

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432
Oana Danciu	1

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Georgetown University	Washington D.C.	United States	21
Medical University of South Carolina	Charleston	United States	628
New York University Clinical Cancer Center	New York	United States	4
Ohio State University Comprehensive Cancer Center	Columbus	United States	548
Orlando Health Cancer Institute	Orlando	United States	97
Parkview Research Center	Fort Wayne	United States	17
Penn State Cancer Institute	Hershey	United States	17
Providence Portland Medical Center	Portland	United States	324
Rutgers Cancer Institute of New Jersey	New Brunswick	United States	223
Tufts Medical Center	Boston	United States	238
University of Alabama at Birmingham	Birmingham	United States	247
University of Arizona	Phoenix	United States	3
University of Illinois Cancer Center	Chicago	United States	34
University of Iowa Hospitals and Clinics	Iowa City	United States	99
University of Michigan Health System	Ann Arbor	United States	38
University of Michigan Health-West	Wyoming	United States	4
University of Nebraska Medical Center	Omaha	United States	397
University of New Mexico Comprehensive Cancer Center	Albuquerque	United States	7
University of Virginia Health System	Charlottesville	United States	57
University of Wisconsin	Madison	United States	64
Virginia Commonwealth University	Richmond	United States	156

Clinical trials